$INDP News

Indaptus Therapeutics Files Prospectus Related To The Resale By The Selling Stockholders Of Up To 18.86M Shares Of Common Stock

Indaptus Therapeutics Entered Stock Sale Agreement To Sell 20M Shares For $0.06/Share; Gross Proceeds Of $12M

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics Q1 EPS $(0.23) Beats $(1.87) Estimate

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Entered Into $6M Securities Purchase Agreement With Investor David Lazar

Indaptus Entered Into $6M Securities Purchase Agreement With Investor David Lazar

What Does the Market Think About Indaptus Therapeutics Inc?

Market-Moving News for December 24th

Indaptus Therapeutics Appoints David Lazar As The Co-Chief Executive Officer

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Q3 EPS $(2.98) Beats $(4.17) Estimate

Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 109.76%

Indaptus Therapeutics Shares Resume Trade

Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 77.13%

Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 50.91%

Indaptus Therapeutics shares are trading lower. The company announced recent updates for its ongoing INDP-D101 clinical trial.

Indaptus Therapeutics Provides Clinical Update

Indaptus Reports Partial Response From Decoy20 Monotherapy In Urothelial Cancer; Combo With PD-1 Inhibitor Shows Favorable Safety